|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Enalapril#Use in Specific Populations]] |
| {{Enalapril}}
| |
| {{CMG}}; {{AE}} {{AM}}
| |
| | |
| ==Specific Population==
| |
| | |
| ====Pregnancy====
| |
| | |
| Pregnancy Categories C (first trimester) and D (second and third trimesters) (see WARNINGS, Fetal/Neonatal Morbidity and Mortality).
| |
| | |
| ====Nursing Mothers====
| |
| | |
| Enalapril and enalaprilat have been detected in human breast milk. Because of the potential for serious adverse reactions in nursing infants from enalapril, a decision should be made whether to discontinue nursing or to discontinue VASOTEC, taking into account the importance of the drug to the mother. | |
| | |
| ====Pediatric Use====
| |
| | |
| Antihypertensive effects of VASOTEC have been established in hypertensive pediatric patients age 1 month to 16 years. Use of VASOTEC in these age groups is supported by evidence from adequate and well-controlled studies of VASOTEC in pediatric and adult patients as well as by published literature in pediatric patients (see CLINICAL PHARMACOLOGY, Clinical Pharmacology in Pediatric Patients and DOSAGE AND ADMINISTRATION).
| |
| | |
| VASOTEC is not recommended in neonates and in pediatric patients with [[glomerular filtration rate]] <30 mL/min/1.73 m2, as no data are available.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VASOTEC (ENALAPRIL MALEATE) TABLET VASOTEC (ENALAPRIL MALEATE) TABLET [BTA PHARMACEUTICALS INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5d181743-a0fc-4d17-953d-b17a936f9ecc | publisher = | date = | accessdate = }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |